Koca, IrfanDokuyucu, RecepTas, Zeynel AbidinGokce, HasanOzcan, Oguzhan2024-08-042024-08-0420202074-18042074-1812https://doi.org/10.5812/ircmj.97279https://hdl.handle.net/11616/102930Background: Osteonecrosis (ON) is a serious health problem, which dramatically reduces the quality of life. Objectives: In the present study on the rat model of glucocorticoids (GCs) -induced ON, we explored the influence of alpha-lipoic acid on serum levels of TGF-fi1 and urotensin-II (U-II) and on histological alteration with respect to fatty degeneration and osteocyte necrosis. Methods: A total of 32 male Wistar albino rats were equally assigned to four groups, including control, methylprednisolone acetate (MPA), alpha-lipoic acid (ALA), and MPA with ALA (MP1 + ALA). The animals in MPA group subcutaneously received 15 mg/kg/week during 2 weeks, whereas 100 mg/kg/day ALA was intraperitoneally administered to ALA group during 4 weeks. The MPA + ALA group had both treatments with the same doses. ON was confirmed and graded histologically. Lipid peroxidation and DNA damage levels were immunohistochemically assessed in rats' bones. Results: After histopathological examinations, ALA injection attenuated oxidative stress levels through reducing both 8-OHdG-and 4-HNE-positive cells in the femoral head region (P < 0.05). The U-II and TGF-fi1 protein levels significantly decreased after ALA treatment in MPA injected animals (P < 0.05, P < 0.01, respectively). Moreover, there was a strong correlation between U-II and TGF-fi 1 protein levels (P = 0.019, r = 0.884). Conclusions: This study is novel with regard to showing the therapeutic effects of ALA on GC-inducedONin rats as well as the strong correlation between the expression levels of U-II and TGF-fi1 proteins. In this regard, ALAmaybe a therapeutic agent in the treatment of ON patients.eninfo:eu-repo/semantics/closedAccessOsteonecrosisAlpha-Lipoic AcidUrotensin-IITGF-beta 1Article22410.5812/ircmj.97279WOS:000532374500004Q4